Mergers & AcquisitionsMedium•8 October 2026•
1 min read
Viatris to Acquire Pacira BioSciences for $1.65 Billion to Expand Pain Therapy Portfolio
Key Facts
1Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash.
2The transaction has an aggregate equity value of approximately $1.65 billion and is expected to close by the end of 2026.
3The deal adds patent-protected medicines EXPAREL and ZILRETTA to Viatris' portfolio of non-opioid pain therapies.
Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash. PR Newswire reported that the transaction has an aggregate equity value of approximately $1.65 billion and is expected to close by the end of 2026. The deal adds patent-protected medicines EXPAREL and ZILRETTA to Viatris' portfolio of non-opioid pain therapies.
PCRX closed at $25.20 on October 7, 2026, while VTRS closed at $17.49 on the same date. The acquisition aims to expand Viatris' innovative medicines strategy and establish leadership in high-margin pain therapies, with Pacira's products expected to be immediately accretive to Viatris' financial guidance upon closing.